Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ACET
ACET
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ACET News
Adicet Bio CEO to Participate in Healthcare Conference
May 14 2026
Yahoo Finance
Adicet Biopress Reports Q1 Earnings Results
May 13 2026
seekingalpha
Adicet Biopress Reports Expanded Net Loss in FY Earnings Release
Mar 12 2026
seekingalpha
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
Jan 06 2026
Benzinga
Adicet Bio Announces 1-for-16 Reverse Stock Split to Maintain Listing Compliance
Dec 26 2025
Benzinga
Adicet Bio (ACET) Approves 1-for-16 Reverse Stock Split to Regain Nasdaq Compliance
Dec 26 2025
NASDAQ.COM
Adicet Bio Implements 1-for-16 Reverse Stock Split to Enhance Nasdaq Compliance
Dec 26 2025
Newsfilter
Adicet Bio Announces 1-for-16 Reverse Stock Split, Reducing Shares to 9.6 Million
Dec 26 2025
Businesswire
Adicet Bio Grants New Employee 20,600 Stock Options at $0.65 Each
Nov 28 2025
Newsfilter
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday
Nov 19 2025
NASDAQ.COM
Guggenheim Upholds Buy Rating for Adicet Bio (ACET)
Oct 09 2025
NASDAQ.COM
Adicet Bio, Inc. Unveils $80 Million Registered Direct Offering
Oct 07 2025
Newsfilter
Adicet Bio Reports Encouraging Initial Results from Phase 1 Trial of ADI-001 in Lupus Nephritis and Systemic Lupus Erythematosus Patients
Oct 07 2025
Newsfilter
Guggenheim Affirms Buy Rating for Adicet Bio, Keeps $7 Price Target Intact
Sep 19 2025
Benzinga
Adicet Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Aug 29 2025
Newsfilter
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Aug 12 2025
NASDAQ.COM
Show More News
